Probiotics with ABCG2 expression ability and gut microbiota homeostasis exhibit anti-hyperuricemia potential by promoting uric acid excretion

Probiotics have been reported to have the potential effect of alleviating Hyperuricemia (HUA). However, due to the complexity of its mechanisms, the research on probiotics with anti-HUA potential is still limited. In this study, administration of Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and Lactobacillus acidophilus NCFM exhibited UA-reducing capacity, as well as lowering creatinine and urease levels and xanthine oxidase (XOD) activity. They effectively contribute to a decrease in pro-inflammatory (IL-1 β and TNF- α ) factors while regulating the expression of transporters, particularly the ATP-binding cassette subfamily G2 (ABCG2). These strains also powerfully restore the gut microbiota, increasing the abundance of the Lactobacillaceae , thus playing a crucial role in HUA reduction by being intensely involved in the expression of ABCG2 transporter. These findings provide a pivotal theoretical basis for elucidating the potential probiotics as dietary supplements to relieve HUA via intestinal remediation. • Probiotic supplements attenuate renal inflammation in hyperuricemia mice. • Fecal microbiome and expression of ABCG2 transporters revealed potential mechanisms for HUA alleviation. • Proposed a new strategy for the potential of probiotics in alleviating HUA.